US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

ホーム
投資
株式
オーストラリア
ASX
Income Asset Management Group Ltd (IAM) 銘柄情報

Income Asset Management Group Ltd (IAM)

0.02

0.00

( 0.00% )

更新日時： 09:14:14

Income Asset Management Group Ltd (IAM) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.02

( - )

買値

0.019

売値

0.02

出来高

1,880,822

0.02 日の範囲 0.02

0.016 52 週間の範囲 0.047

時価総額

前日終値

0.02

始値

0.02

時刻

最終取引時間

09:22:41

財務取引量

-

VWAP

-

平均取引量 (3 か月)

AUD 553,830

発行済株式数

930,870,820

配当利回り

PER

-5.14

1 株当たり利益 (EPS)

-0

歳入

18.22M

純利益

-3.87M

Income Asset Management Group Limited provides financial product solutions in cash/deposits and fixed income in Australia. It offers licenses for margin lending, foreign exchange, derivatives trading, and market-making. The company also provides access to wholesale markets across bonds and loans, in... Income Asset Management Group Limited provides financial product solutions in cash/deposits and fixed income in Australia. It offers licenses for margin lending, foreign exchange, derivatives trading, and market-making. The company also provides access to wholesale markets across bonds and loans, including asset backed securities, residential mortgage-backed securities, and managed discretionary accounts. It serves wholesale, sophisticated clients, and professional investors. The company was formerly known as Cashwerkz Limited and changed its name to Income Asset Management Group Limited in August 2021. Income Asset Management Group Limited was incorporated in 1986 and is based in Sydney, Australia. 詳細を表示

セクター

Finance

業界

Asset Management Services

ウェブサイト

www.incomeam.com

本社

Sydney, Australia

設立

1986

Income Asset Management Group Ltd is listed in the Finance sector of the オーストラリア証券取引所 with ticker IAM. The last closing price for Income Asset Management was AUD0.02. Over the last year, Income Asset Management shares have traded in a share price range of AUD 0.016 to AUD 0.047.

Income Asset Management currently has 930,870,820 shares in issue. The market capitalisation of Income Asset Management is AUD18.62 million. Income Asset Management has a price to earnings ratio (PE ratio) of -5.14.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0.02	0.022	0.02	1121417	0.022	DE
4	0.001	5.26315789474	0.019	0.022	0.018	474316	0.0206818	DE
12	-0.002	-9.09090909091	0.022	0.023	0.016	601291	0.01988881	DE
26	-0.011	-35.4838709677	0.031	0.038	0.016	515369	0.02580568	DE
52	-0.005	-20	0.025	0.047	0.016	961054	0.03294805	DE
156	-0.11	-84.6153846154	0.13	0.155	0.016	697542	0.03719587	DE
260	-0.27	-93.1034482759	0.29	0.31	0.016	527786	0.04958701	DE

IAM - Frequently Asked Questions (FAQ)

What is the current Income Asset Management Group Ltd share price?

The current share price of Income Asset Management Group Ltd is AUD 0.02

How many Income Asset Management Group Ltd shares are in issue?

Income Asset Management Group Ltd has 930,870,820 shares in issue

What is the market cap of Income Asset Management Group Ltd?

The market capitalisation of Income Asset Management Group Ltd is AUD 18.62M

What is the 1 year trading range for Income Asset Management Group Ltd share price?

Income Asset Management Group Ltd has traded in the range of AUD 0.016 to AUD 0.047 during the past year

What is the PE ratio of Income Asset Management Group Ltd?

The price to earnings ratio of Income Asset Management Group Ltd is -5.14

What is the cash to sales ratio of Income Asset Management Group Ltd?

The cash to sales ratio of Income Asset Management Group Ltd is 1.12

What is the registered address of Income Asset Management Group Ltd?

The registered address for Income Asset Management Group Ltd is 4 Martin Place, Sydney, New South Wales, 2000

What is the Income Asset Management Group Ltd website address?

The website address for Income Asset Management Group Ltd is www.incomeam.com

Which industry sector does Income Asset Management Group Ltd operate in?

Income Asset Management Group Ltd operates in the Asset Management Services sector

biosectinvestor

biosectinvestor 4分前

That sidesteps the point.

I am not defending every theory posted by every investor about the MHRA timeline. I am addressing your categorical argument: no tissue-agnostic biomarker, therefore no tissue-agnostic or platform pathway.

That argument still fails.

bluebird50

bluebird50 6分前

I think the winner here is a Deutche bank London transfer to California investors…
Big win maybe or a big wind down???
I’m sure the transaction even 10 cents on the dollar is 100 million plus… how long they want to sit on that investment?? Back in March.
I seen on the filing

jxyzobrien

jxyzobrien 6分前

in the morning trade brigade does
market take so i do not need this guy

Cheef Zed

Cheef Zed 7分前

Not surprised to see this dip after no one buying those 03s ! Waiting for some juicy updates hopefully 🤞

Just give me $1.50

Just give me $1.50 8分前

Keep your eyes peeled for the CC press release either tomorrow morning or Thursday morning.

June 15: 10-K
June 16: Mikah conference call

Thanks.

12yearplan

12yearplan 9分前

Good to go https://eservices.bcsc.bc.ca/eservices/docview/temp/BCSC_ReportingIssuers.pdf?t=1591900504955

biosectinvestor

biosectinvestor 10分前

You are not identifying a regulatory impossibility; you are identifying that DCVax does not fit a pathway FDA created for a different new class of drugs. That is not a rebuttal to the platform thesis. It is the class error.

----

So , no, this is not about verbiage. It i

haras

I guess it is fair to say : Kiss it good bye. 4 years in the waiting for nothing what a shame…

Duke Knockem

Duke Knockem 13分前

alright well go on Twitter and make a judge Judy of yourself man there only OTC retards on here and that includes myself

floblu14

floblu14 15分前

Addendum - from AI
Hearing Date: The UPC hearing is set for September 29, 2026, with a decision anticipated from the court within weeks following the hearing.

Mistervane

Mistervane 15分前

Not an obituary. Still speculation. “I’m hearing…” is not factual information.

Fangster

Fangster 16分前

Excellent find, Yoda! Great potential connection direct to the president.

satter

satter 17分前

I am not sure how the silver mine deal proceeds or others.

Since Hiru never posted a bond the plaintiff could have gone after assets at any time. I was surprised there was no prior activity. It appears they were either waiting for the appeal to conclude or doing investigative work.

ErnieBilco

ErnieBilco 17分前

Scinai Immunotherapeutics Ltd.
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jerusalem
Israel

www.scinai.com

Cheef Zed

Cheef Zed 17分前

Interesting action lately … need some updates from company !!

ErnieBilco

ErnieBilco 18分前

Scinai Immunotherapeutics Ltd. is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases.

peafunke

peafunke 19分前

Good… I’ll keep buying.

Duke Knockem

Duke Knockem 19分前

https://x.com/i/status/2063989669667180674

Duke Knockem

Duke Knockem 19分前

https://x.com/i/status/2063989669667180674

17yearsnomoney

17yearsnomoney 19分前

I try to post on the RKT board however if you dare to call out the liars and misinformation that’s been posted for 17 years you end up here.

Crapola2theleft

Crapola2theleft 20分前

Sure sounds like projection !

JTORENCE

JTORENCE 20分前

brooktrail1933 The U.K. is not a big fan of the U.S. Add to that there are more than 5 million Muslims living in the U.K. Could one guess that at least 25% are anti American? Of those 25%, how many does the MHRA employ?
NWBO is a US company. Doesn't take much of an imagination to see th

biosectinvestor

biosectinvestor 21分前

I agree 100% Chiugray. They can whistleblow on their peers and who they are working with and way many, many times what they are now, likely a fortune, IMHO. Have a wonderful day!

floblu14

floblu14 22分前

There is an upcoming public oral hearing scheduled in Enanta Pharmaceuticals' European patent infringement case against Pfizer over the COVID-19 antiviral drug Paxlovid.

The Unified Patent Court (UPC) of the European Union has scheduled the hearing for September 29, 2026.Case Details:

mascale

mascale 24分前

Satter claim that USA has no courts(?): not literacy.

Income Asset Management

Leverage Shares 3x Long ...

Algonquin Fixed Income 2...

Samsung Elect (PK)

Advanced Micro Devices C...

Canadian Equity Value Co...

Brandes Corporate Focus ...

European Natural Gas

Japan Post Insurance

Ci High Yield Bond Corpo...

Xtrackers MSCI Japan ESG...

3000% until 05/11/2029

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。